- 5 Cancelled Shows That Are Returning and 13 We Wish Would Come Back
- Donald Trump May Have Had His 'Oops' Moment Over Mexico
- Does Apple Have a Watch Problem?
- MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin
- Has Trump's Presidential Bid Already Backfired? A Billion-Dollar Brand Turned Toxic
The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.
Juno shares are rising after the company signed a 10 year $1 billion drug development deal with Celgene (CELG).
Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.
Seres Therapeutics (MCRB) shares came back down to earth after spiking more than 65% in its initial day of trading on Friday.
Papa Johns is the latest big food brand to clean up its act and cut down on artificial ingredients as consumers become more health conscious.
Gilead Sciences (GILD) shares are down after two groups sued the FDA to allow the release of the clinical trial data related to its two costly hepatitis C treatments.
Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.
Both companies belong on investors' radar, especially before they go ex-dividend this week.
New Sarepta CEO Ed Kaye filed for approval of eteplirsen with the FDA as promised, allowing him to check off a hugely important item on the company's to-do list.
Jim Cramer and Jack Mohr love Target (TGT) and it's one stock in the Action Alerts PLUS portfolio that has been bringing in big money.
Executive compensation and shareholder returns don't always move in the same direction, and sometimes it's the CEOs who appear to get the short end of the stick.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Shares of Tenet Healthcare (THC) wrapped up Thursday's trading day to the upside, by more than a dozen percent on very heavy volume.
Here are some of the worst companies TheStreet Quant Ratings says you should consider selling.
Baxter Int'l. (BAX) shares are rising after the company reported positive results from its hemophilia B treatment trials.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV